Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor
- 16 October 2024
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 47-52
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
- National Institutes of Health
- Sun Pharma
This publication has 28 references indexed in Scilit:
- Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosisJournal of Cystic Fibrosis, 2020
- Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysisJournal of Cystic Fibrosis, 2020
- Energy balance and obesity in individuals with cystic fibrosisJournal of Cystic Fibrosis, 2019
- The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacityJournal of Cystic Fibrosis, 2019
- Coronary artery disease in cystic fibrosis: An emerging concern?Journal of Cystic Fibrosis, 2016
- Prevalence of dyslipidemia in adults with cystic fibrosisJournal of Cystic Fibrosis, 2010
- Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD)Journal of Cystic Fibrosis, 2008
- Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic ReviewJournal of the American Dietetic Association, 2008
- Metabolic Syndrome and Risk of Incident Cardiovascular Events and DeathJACC, 2007
- Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosisJournal of Cystic Fibrosis, 2006